Introduction
. These substances undergo intracellular anabolic phosphorylation to produce 5′-triphosphorylated forms (ddNTP), which competitively block the endogenous cellular substrate, deoxynucleoside triphosphate (dNTP), from binding to RT (Back et al., 1995) . The ddNTPs are incorporated into the elongating DNA strands during synthesis of the DNA copy of the viral genome by RT, resulting in premature chain termination. The ddNTP to dNTP ratio critically determines drug activity and varies in different cells (Perno et al., 1994; Kewn, et al., 1999) . Changes in the proportion of ddNTP to dNTP can affect the efficacy of the NRTIs, one reason for the different activities of a drug against the same virus in different cell types (Tsai et al., 1990) .
Six currently licensed NRTIs used successfully in HIV-1 infected individuals to reduce plasma viral load and to slow progression to AIDS (Fischl et al., 1987; Delta Coordinating Committee, 1996; Katlama et al., 1996; Saag et al., 1998; Staszewski et al., 1996) are: AZT (3′-azido-2′,3′-dideoxythymidine); ddI (2′,3′-dideoxyinosine); ddC (2′,3′-dideoxycytidine); d4T (2′,3′-dideoxy-2′,3′-didehydrothymidine); 3TC (2′-deoxy-3′-thiacytidine); and ABC (1592U89 succinate; abacavir) . Surprisingly, little is known about the effects of these compounds on retroviruses other than HIV.
The use of NRTIs in treating another common human retroviral infection mediated by human T cell leukaemia virus type I (HTLV-I), has so far been confined to 3TC and AZT in small studies with varying degrees of success (reviewed in Gout et al., 1991; Sheremata et al., 1993; Taylor, 1998) . Simian immunodeficiency virus (SIVmac251) was sensitive to AZT and d4T (Tsai et al., 1990) , two compounds that are thought to have similar metabolic pathways (Furman et al., 1986; Marongiu et al., 1990) . Other studies have documented antiviral activity of AZT and ddC against SRV-2 in vitro (Tsai et al., 1988) , but not in vivo when given as monotherapy (Tsai et al., 1989) . More recently, it was claimed that ddI and AZT inhibited HFV in acutely infected cells (Santillana-Hayat et al., 1996) , while others failed to confirm the effect of ddI on HFV infection in vitro (Yu et al., 1999) .
An investigation that compares the potency of these compounds across a range of retroviruses is overdue, since most studies have limited their antiviral activity investigations to one or two NRTIs for any specific retrovirus. Such studies could allow the choice of appropriate antiviral compounds to enable the further characterization of retrovirus replication cycles (Yu et al., 1999) , and investigating antiviral potency for a variety of retroviruses would help to establish a likely efficacy range for undiscovered human retroviruses. We therefore examined the inhibitory activity of all licensed NRTIs against representatives from each traditional subfamily. Viruses in this study are known to cause immunodeficiency diseases in macaques (SRV-1 and SRV-2) (reviewed in Rosenblum & McClure, 1999a) and thymic leukaemia and lymphoma in mice (MLV-A) (Moloney, 1966) , while the pathological potential of SFV-1, SFV-6 and HFV, viruses found in many primates, remains undefined (reviewed in Rosenblum & McClure, 1999b ). Antiviral compounds were tested at various concentrations, including concentrations below those known to inhibit HIV infection.
Materials and Methods

Cells
Human T-lymphoblastoid cells (C8166) (Salahuddin et al., 1983) , Burkitt-lymphoma B-cells (Raji) (Epstein et al., 1966) and a Hut 98 cell clone (H9) (Popovic et al., 1984) were maintained in RPMI 1640 medium (Gibco) supplemented with L-glutamine (2 mM), penicillin (250 mM), streptomycin (50 µg/ml) and 10% foetal calf serum (FCS) (Gibco). Mink lung fibroblasts (Mv-1-Lu) (Darai & Flugel, 1978) , human TE671 cells (Ammirati et al., 1980) , human lung carcinoma cells (A549) (Lieber et al., 1976) , baby hamster kidney fibroblasts (BHK-21) (Macpherson & Stoker, 1962) and BHK-21 cells containing HFV LTR-β-Gal DNA (FAB) (Yu & Linial, 1993) were maintained in Dulbecco's modified Eagle medium (DMEM) (Gibco) with either 10% FCS (Mink, TE671, and A549) or 5% FCS (BHK-21 and FAB). Human embryonic lung fibroblasts (HEL) were grown in minimal essential medium (MEM) (Gibco) supplemented with 10% FCS, non-essential amino acids (1%) and sodium phosphate (1 mM). Cells were propagated at 37 o C with 5% CO 2 .
Virus isolates
Virus stocks (Table 1) were prepared by infection of host cells in 25 cm 2 flasks at a multiplicity of infection (m.o.i.) of 0.01-0.1. Virus was harvested from culture supernatants 2 or 3 days after the appearance of syncytia (multinucleated giant cells), or after cell confluence (MLV-A). Cell suspensions were clarified by centrifugation (500 g, 5 min) and viruscontaining supernatants were cryo-preserved. Virus stocks were titrated by end-point dilution assays on specific target cells (Table 1) , as described (Hierholzer & Killington, 1996) . Fifty per cent tissue culture infectious dose (TCID 50 ) values were calculated for each virus by the Spearman-Karber method (Hierholzer & Killington, 1996) .
Optimum virus production
One hundred TCID 50 for each virus was used to infect appropriate cells (Table 1) . Optimum virus production was evaluated to ensure consistency throughout the study. RT activity in cell-free supernatants was assayed daily for 10 days post-infection. LL Rosenblum et al. Cell viability was determined by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (Sigma) (Pauwels et al., 1988) . Healthy cells reduce MTT producing a dark colour, which is assayed spectrophotometrically (A 540 -A 690 ). Briefly, pretreated cells were incubated (37 o C, 5% CO 2 ) for 2 h before adding 20 µl MTT (7.5 mg/ml in PBS). After an incubation for 30 min at 37 o C, 150 µl of supernatant were removed and added to 100 µl of 10% Triton X-100 (0.4% in isopropanol). Following a 10-min incubation at 37 o C to release the reduced MTT, samples were assessed colorimetrically.
Antiretroviral agents
AZT, 3TC and ABC were generously provided by GlaxoSmithKline, Hertfordshire, UK; ddI and ddC were purchased from Sigma Chemical; and d4T was a kind gift from Dr Michael Thompson at Bristol-Myers Squibb Pharmaceuticals, Middlesex, UK. Compounds were dissolved in 1 ml dimethyl sulphoxide (DMSO) (Sigma), and diluted in RPMI, to yield 10 or 20 mM stocks. Half-log dilutions of each compound were made so that the final concentrations were 100, 32, 10, 3.2, 1, 0.32, 0.1 and 0.032µM per well.
Inhibition assays
After cells were distributed in microtitre plates (Corning), detailed in Table 1 , drugs were added at one quarter of the final volume, in duplicate. Pretreated cells were incubated (37 o C, 5% CO 2 ) for 2 h, virus added, and incubated further for 4 days. The amount of virus inhibition was determined by RT activity (Ekstrand et al., 1996; Malmsten et al., 1998) , by inhibition of syncytium formation (Hierholzer & Killington, 1996) or by inhibition of antigen expression using immunofocal assays (Bieniasz et al., 1995) as indicated (Table 1) , and described below. The assays were repeated at least three times. Controls, included with each experiment, consisted of untreated infected and uninfected cells. (Ekstrand et al., 1996; Malmsten et al., 1998) . Briefly, infected supernatants from RT inhibition assays were diluted 1:1 with the lysis buffer provided. Diluted samples were pretreated with the polyadenylic acid [poly(rA)], a template for the incorporation of the nucleoside analogue, 5-bromo-deoxyuridine triphosphate (BrdUTP) via a primer, oligo(dT)22. After 1h incubation, incorporated product was quantitatively detected by adding alkaline phosphatase-conjugated antiBrdU monoclonal antibody, which acts on the substrate, p-nitrophenyl phosphate, yielding a colorimetric change detected at 405 nm.
(ii) Syncytial induction (SI) assay. SI assays were used to detect the inhibition of HIV and SRV-induced CPE in non-adherent cells as previously described (Hierholzer & Killington, 1996) . Large, virus-induced, multinucleated syncytia formed in Raji and C8166 cells up to 7 days postinfection. Cells were scored visually to assess the proportion of syncytial cells.
(iii) Immunofocal (IF) assay. HFV infection was assayed by IF, as described (Bieniasz et al., 1995) . Cells were fixed for 10 min with 500 µl ice-cold 1:1 acetone:methanol, after which the fixative was aspirated and cells were air-dried. Cells were washed in phosphate-buffered saline (PBS/1% FCS) and incubated for 45 min at room temperature with human antisera (1:200 in PBS/1% FCS). Cells were washed three times in PBS/1% FCS, before a further 45 min incubation with goat anti-human IgG conjugated to horseradish peroxidase (1:100 in PBS/1% FCS). After four 
Results
Determination of drug toxicity
Cytotoxic drug levels were established for all drugs for each of the cell lines prior to the commencement of the inhibition assays (data not shown). Certain antiviral compounds produced toxicity at the highest concentrations tested. Concentrations of 100 µM ddC and 100 µM AZT produced 48 and 42% growth inhibition of Raji cells, and 49 and 38% of Mink cells, respectively. At a concentration of 100 µM, ABC produced 84% growth inhibition of Mink cells. There were no significant differences in the levels at which toxicity developed between the different cell lines used in the study.
Comparison of different assays for detection of infectivity
Different assay systems were compared in order to determine drug-induced inhibition of HIV-1 MN, HFV and SRV-2 (Table 1) . On day 4 post-infection, the antiviral effect was measured by RT and SI or IF assays, as indicated (Table 1) . RT assays determined reverse transcriptase activity in cell-free supernatants (Ekstrand et al., 1996; Malmsten et al., 1998) , while viral antigen expression in cell cultures were determined by SI (Hierholzer & Killington, 1996) and IF (Bieniasz et al., 1995) assays. For all viruses, the inhibition of RT in cell-free supernatants compared well with the inhibition of SI or detection of antigen by IF (Table 2) . To determine the extent to which antiviral agents exhibit different properties in different cells, BHK-21 and HEL cells were used to evaluate the efficacy of drugs against HFV. Drugs were up to 10-fold less effective in HEL cells compared with BHK-21 when this was assessed by IC 50 determination, but the differences virtually disappeared when IC 90 values were measured (Table 2) . IC 50 and IC 90 values remained consistent from experiment to experiment.
IC 50 and IC 90 comparisons
The IC 50 values obtained for HIV-1 MN against all compounds were in line with those reported previously by other groups (Table 2) , and indicated that AZT was the most effective compound against HIV-1, each of the foamy viruses and MLV-A. However, ddC and 3TC were most effective for SRV-1, SRV-2 and HIV-1 (magnesiumdependent viruses) and were less active for the foamy viruses and MLV-A (manganese-dependent viruses). MLV-A was resistant to d4T, but highly sensitive to AZT. Abacavir effectively inhibited most viruses, particularly HIV-1 (IC 50 =0.32 µM) and SFV-6 (IC 50 =0.32 µM).
Using IC 90 values (Table 2) , AZT proved to be the most potent inhibitor (IC 90 range, 0.032-32 µM), especially against the foamy viruses (IC 90 range, 0.032-3.2 µM). The least active drug, 3TC (IC 90 range, 1.0-100 µM), was most effective against SRV-1, SRV-2 and HIV-1 (IC 90 range, 1.0-10 µM), and least effective against foamy viruses and MLV-A (IC 90 100 µM) ( Table 2 ). Like 3TC, ddC and d4T were most effective against the SRVs and HIV-1 (IC 90 range: for ddC, 0.32-3.2 µM; and for d4T, 10 µM). The SRVs were sensitive to ddI, with IC 90 values threefold less than that for HIV-1 (Table 2) . Even though d4T and AZT employ the same phosphorylating enzymes during metabolism (Hoetelmans, 1999) , higher concentrations of d4T, compared with AZT, were almost always required to generate 90% inhibition. Abacavir was highly active against HIV and MLV-A, but surprisingly, only one foamy virus (SFV-6) (IC 90 range, 3.2-10 µM), and was moderately active against the SRVs, HFV and SFV-1 (IC 90 =32 µM).
Discussion
The data presented show that NRTIs inhibit the replication of different retroviruses to varying degrees. The NRTIs investigated were developed specifically to target HIV-1 RT with the exception of AZT, which was initially designed as an anti-tumour agent (Mitsuya et al., 1985) . LL Rosenblum et al. 4 ©2001 International Medical Press Although they might be expected to have some degree of activity against all retroviruses, it was surprising that in this study, other viruses showed greater susceptibility to certain drugs than HIV-1. Ideally, this analysis would have assessed the sensitivity of retroviruses to a panel of antiretroviral drugs within one cell type, using identical culture conditions and the same measure of inhibition. Biological constraints prohibit this, and therefore, certain variables were required to be incorporated. A number of factors may influence the sensitivity of a virus to a nucleoside inhibitor in a particular cell type. These include the concentration of the drug triphosphate achieved (which depends on the rates of phosphorylation and degradation), the concentration of natural triphosphate with which the drug competes and the affinity of the RTs of each retrovirus for the drug triphosphate.
The first two of these factors have implications for the cell lines chosen to assay drug sensitivity. Six cell types were used (Raji, BHK-21, HEL, FAB, Mink and C8166) to test the seven viruses. Although these were all mammalian cell lines, different rates of drug uptake, phosphorylation and degradation cannot be excluded. Differences in the endogenous levels of the relevant kinases and phosphorylases required to transform the NRTIs into their active triphosphate (TP) form may exist in the different cell types (Dahlberg et al., 1987) . For example, AZT is rapidly phosphorylated by cellular thymidine kinase (TK) to AZTmonophosphate (AZT-MP), which in turn, acts as a substrate for further catalysation to the di-and triphosphate forms (Lavie et al., 1997) by host cell thymidylate kinase (TdK) (Furman et al., 1986) . The production of the active drug moiety from AZT is therefore modulated by three cellular enzymatic reactions, potentially producing variability between cell lines.
Despite both being analogues of thymidine, d4T produced weaker inhibition than AZT, possibly reflecting the variation in intracellular processing of antiretrovirals between drug classes. Although the rate-limiting step in the phosphorylation of AZT is at the TdK level, that of d4T is TK (Ho & Hitchcock, 1989) , a difference that may be important to the susceptibility of viruses to AZT and d4T. Despite this, higher levels of d4T in its active TP form have been reported to accumulate intracellularly, and therefore, other factors need also to be considered.
In this study, the lack of significant differences in the levels of drug required to produce toxicity in the different cell lines may indicate similar intracellular metabolism of the drugs at the concentrations used. In addition, the comparison of BHK-21 and HEL cell lines for assaying inhibition of HFV produced variability in IC 50 values of no greater than 1 log 10 , and IC 90 values that were equivalent for all drugs except AZT. Therefore, the data presented permit an approximate comparison of the degree to which individual retroviruses are inhibited by the same drug.
The analysis of the degree of inhibition of each virus to the panel of drugs, involved less variability as the same cell line was used for each virus. For the majority of viruses (except SRV) AZT was the most potent inhibitor of replication at the IC 50 and IC 95 level. HIV was also inhibited by 3TC, ddC and ABC (IC 50 , 0.32), d4T (IC 50 1.0-3.2) and ddI (IC 50 3.2-10), however the other retroviruses showed different hierarchies of drug inhibition. The most effective NRTI against both SRV-1 and SRV-2 was ddC (one half log more active than AZT). Other in vitro studies on SRV-2 have also shown that AZT and ddC inhibit viral infectivity (Tsai et al., 1988) . Of the viruses that were most susceptible to AZT, the second most potent drugs varied (ddC, ddI or d4T for HFV and ABC, ddI or ddC for SFV-1, SFV-6 and MLV). These differences may reflect varying affinities for the different viral RT active sites. Polymorphic genetic variability at the drug binding site will impact on the degree of drug binding and, as the NRTIs are competitive inhibitors, may favour binding of the natural host NRTI triphosphates.
Apart from HIV-1 and SRV-2, retroviruses were resistant to 3TC with IC 50 and IC 95 values greater than 100 µM (except for 10 µM for SRV-1) ( Table 2) . Mutations in the HIV-1 RT protein that confer resistance to NRTIs are well established (Frater et al., 1999; Boucher et al., 1993; Schinazi et al., 1999) . The major HIV-1 mutation associated with resistance to 3TC is M184V, occurring in the RT active site YMDD motif (Schuurman et al., 1995) . HFV possesses the YVDD motif (Yu et al., 1999) , which also confers resistance to 3TC. The lack of SFV or MLV inhibition by 3TC suggests that these viruses may carry similar mutations. The M184V mutation is also associated with reduced susceptibility to ddI and ddC in HIV-1 (Schinazi et al., 1999) and this may explain HFV resistance to ddI. Our data support the findings of Yu et al. (1999) who stated that ddI is not active against HFV, but not the findings of Santillana et al. (1996) who found that ddI inhibited HFV in H9 cells. One possible explanation for these discrepancies may the different cell-lines used, which, as discussed above, may confer selective drug advantage.
The activity of ABC was unusual as this compound was the second most potent at inhibiting HIV, MLV, SFV-1 and SFV-6, but ranked fourth or fifth for HFV, SRV-1 and SRV-6. The reason for this differential susceptibility to ABC is difficult to explain, especially since HFV and SFV-6 are thought to be closely related on the basis of neutralization and immunofluorescence microscopy (Nemo et al., 1978) , as well as sequence data and functional characteristics (Bieniasz et al., 1995) . However, ABC was the only 2′-deoxyguanosine analogue in the panel of drugs tested, and is phosphorylated by a unique metabolic pathway to carbocyclic guanosine triphosphate, a potent inhibitor of HIV-1 reverse transcriptase (Faletto et al. 1997) . This unique mode of inhibition may relate to the unusual inhibitory pattern in the different retroviruses.
In conclusion, NRTIs have a wide spectrum of antiretroviral activity. While these drugs have been developed primarily for clinical use in treating HIV-1 infection, it is helpful to study sensitivities of other retroviruses to these drugs in order to establish a range of activity for use not only in vitro, but also with the potential for treatment of infection.
